Current issues in the economics of vaccination against dengue

Research output: Contribution to journalReview article

Abstract

Dengue is a major public health concern in tropical and subtropical areas of the world. The prospects for dengue prevention have recently improved with the results of efficacy trials of a tetravalent dengue vaccine. Although partially effective, once licensed, its introduction can be a public health priority in heavily affected countries because of the perceived public health importance of dengue. This review explores the most immediate economic considerations of introducing a new dengue vaccine and evaluates the published economic analyses of dengue vaccination. Findings indicate that the current economic evidence base is of limited utility to support country-level decisions on dengue vaccine introduction. There are a handful of published cost-effectiveness studies and no country-specific costing studies to project the full resource requirements of dengue vaccine introduction. Country-level analytical expertise in economic analyses, another gap identified, needs to be strengthened to facilitate evidence-based decision-making on dengue vaccine introduction in endemic countries.

Original languageEnglish (US)
Pages (from-to)519-528
Number of pages10
JournalExpert Review of Vaccines
Volume15
Issue number4
DOIs
StatePublished - Apr 2 2016

    Fingerprint

Keywords

  • Dengue vaccination
  • affordability
  • cost-effectiveness
  • dengue
  • dengue vaccines
  • developing countries
  • economic evaluation
  • low- and middle-income countries
  • national immunization programs
  • sustainability

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this